首页 | 本学科首页   官方微博 | 高级检索  
     


N-Arylpiperazine modified analogues of the P2X7 receptor KN-62 antagonist are potent inducers of apoptosis of human primary osteoclasts
Authors:Letizia?Penolazzi,Ercolina?Bianchini,Elisabetta?Lambertini,Pier?Giovanni?Baraldi,Romeo?Romagnoli,Roberta?Piva,Roberto?Gambari  author-information"  >  author-information__contact u-icon-before"  >  mailto:gam@unife.it"   title="  gam@unife.it"   itemprop="  email"   data-track="  click"   data-track-action="  Email author"   data-track-label="  "  >Email author
Affiliation:(1) Department of Biochemistry and Molecular Biology, Molecular Biology section, University of Ferrara, 44100 Ferrara, Italy;(2) Department of Pharmaceutical Sciences, University of Ferrara, 44100 Ferrara, Italy;(3) Interdisciplinary Center for the Study of Inflammation (ICSI), University of Ferrara, 44100 Ferrara, Italy;(4) ER-GenTech, University of Ferrara, 44100 Ferrara, Italy
Abstract:Summary The P2X7 nucleotide receptor is an ATP-gated ion channel that plays an important role in bone cell function. Here, we investigated the effects of L-tyrosine derivatives 1–3 as potent P2X7 antagonists on human primary osteoclasts. We found that the level of expression of P2X7 receptor increased after treatment with the derivatives 1–3, together with the induction of high levels of apoptosis. This effect is associated with activation of caspase-3 and inhibition of expression of IL-6. Interestingly, no pro-apoptotic effect of compounds 1–3 was found on human osteoblasts. Our results suggest that the development of specific P2X7 receptor antagonists may be considered a useful tool to modulate apoptosis of human osteoclasts. Since bone loss due to osteoclast-mediated resorption represents one of the major unsolved problem in osteopenic disorders, the identification of molecules able to induce apoptosis of osteoclasts is of great interest for the development of novel therapeutic strategies.
Keywords:apoptosis  osteoclasts  P2X7 receptor
本文献已被 PubMed SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号